OTCMKTS:BPMUF Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis $52.83 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesShort Interest About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Basilea Pharmaceutica alerts:Sign Up Key Stats Today's Range$52.83▼$52.8350-Day Range$52.83▼$52.8352-Week Range$38.60▼$52.83VolumeN/AAverage VolumeN/AMarket Capitalization$695.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewBasilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Read More… Receive BPMUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMUF Stock News HeadlinesFull Year 2024 Basilea Pharmaceutica AG Allschwil Earnings Call TranscriptFebruary 19, 2025 | gurufocus.comBasilea projects CHF220M in 2025 revenue with key pipeline advancements and U.S. launch of ZevteraFebruary 18, 2025 | msn.comAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what he might do next. And one widely followed Boston based think tank is stepping forward with their official playbook.February 23, 2025 | Altimetry (Ad)Kepler Capital Remains a Buy on Basilea Pharmaceutica (BSLN)February 9, 2025 | markets.businessinsider.comStrong launch for Cresemba in Japan triggers first sales milestone payment from AKP to BasileaFebruary 5, 2025 | finance.yahoo.comStrong sales growth for Cresemba and Zevtera trigger further milestone payments to BasileaJanuary 28, 2025 | uk.finance.yahoo.comBasilea provides portfolio update and outlookJanuary 8, 2025 | finance.yahoo.comKepler Capital Sticks to Their Buy Rating for Basilea Pharmaceutica (BSLN)December 21, 2024 | markets.businessinsider.comSee More Headlines BPMUF Stock Analysis - Frequently Asked Questions How have BPMUF shares performed this year? Basilea Pharmaceutica's stock was trading at $52.83 at the beginning of 2025. Since then, BPMUF stock has increased by 0.0% and is now trading at $52.83. View the best growth stocks for 2025 here. Does Basilea Pharmaceutica have any subsidiaries? Basilea Pharmaceutica subsidiaries include these companies: Conec UK Limited. How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today2/23/2025Next Earnings (Estimated)4/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BPMUF CUSIPN/A CIKN/A Webwww.basilea.com Phone(161) 606-1111Fax41-61-606-1112Employees147Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio5.70 Current Ratio4.10 Quick Ratio3.27 Sales & Book Value Annual Sales$175.50 million Price / Sales3.96 Cash Flow$1.13 per share Price / Cash Flow46.75 Book Value($0.94) per share Price / Book-56.20Miscellaneous Outstanding Shares13,170,000Free FloatN/AMarket Cap$695.77 million OptionableNot Optionable Beta0.74 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (OTCMKTS:BPMUF) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Basilea Pharmaceutica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.